-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Meeting News
-
TTLC Keynote Speaker Explores Progress, Potential Breakthroughs of SCLC Therapies
During the Targeted Therapies of Lung Cancer meeting, MD Anderson’s Dr. Lauren Byers celebrated recent advances and highlighted areas in need of further research.
-
Experts Debate TKI Use After Disease Progression for Patients with EGFR Mutations
During TTLC 23, Drs. Balazs Halmos and Mark Socinski presented the evidence for and against continued tyrosine kinase inhibitors use with chemotherapy for EGFR-positive patients with disease progression.
-
Scenes from TTLC 2023
Revisit all your favorite moments from #TTLC23 in our photo gallery.
-
TTLC 2023 Showcases Early Ongoing Trial Data, Newest Therapies
Conference chairs Drs. Paul Bunn, Charu Aggarwal, Lecia Sequist, and Joel Neal discuss what makes this meeting unique and share program highlights in a recent Q&A with ILCN.
-
In Brief for Feb. 22, 2023
IASLC is now accepting abstract submissions for WCLC 2023 and nominations for committee membership and leadership.
-
Increasing Evidence Demonstrates the Usefulness of ctDNA
LALCA participants recap how the field of liquid biopsy continues to grow—from new biomarkers to new frontiers in early cancer detection.
-
Education Award Recipients Recognized at Latin America Conference
During the Closing Ceremony, five early-career, trainee, or resident investigators were honored for presenting at LALCA 2023.
-
Latin America Conference Attendees Gather Face-to-Face for First Time Since 2019
As LALCA 2023 gets under way in Montevideo, Uruguay, hear from chairs Drs. Luis Ubillos, Mario Varangot, Clarissa Mathias, and Carlos Barrios about the science that will be discussed.
-
Despite Evidence of Benefit, Developing Countries Often Lack Routine Lung Cancer Screening Practices
Expert panel to discuss challenges and opportunities for increasing LDCT screening in Latin America during LALCA 2023.
-
Presidential Symposium Features Best of Abstract Submissions
Highlighted studies explore the association of TP53 mutations with inferior prognosis in NSCLC patients of African ancestry, the possibilities for next-generation sequencing to guide therapy, and the use of a 12-gene expression panel to predict treatment benefit.